BRIDGEWATER, N.J.--(BUSINESS WIRE)--Oct 18, 2016--Amneal Pharmaceuticals LLC (“Amneal”) announced that its newest women’s health product, Yuvafem ® (estradiol vaginal inserts, USP) 10 mcg, began shipping on October 17 th to distributors, wholesalers and directly to the trade.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161018005667/en/
Amneal’s Yuvafem® vaginal inserts, the first-to-market generic for Vagifem® (Photo: Business Wire)
This first-to-market generic equivalent for Vagifem ® delivers the same low dose of vaginal estrogen as the brand in a preloaded, single-use, disposable applicator. The Amneal product is packaged in 8- and 18-count sizes to provide appropriate quantities for both new and maintenance prescriptions.
Prior to approving the Amneal ANDA for Yuvafem ®, FDA required a clinical endpoint study, which the company successfully completed. Amneal R&D efforts are dedicated to making these types of complex medicines more affordable and accessible to patients by bringing the generic equivalent to market.
“Patients and healthcare providers have been eager to see a generic for this unique dosage form in order to benefit from the cost savings such multi-source products can deliver,” said Chirag Patel, Amneal co-CEO and chairman. “As a company, we are not only pleased to be able to offer a potentially more affordable option in this therapeutic category, but to add to our rapidly-growing portfolio of oral contraceptives and hormone replacement therapies in such a significant way.”
Annual U.S. sales of Vagifem ® were $423 million, according to July 2016 IMS market data.
Amneal Pharmaceuticals LLC, a privately-held company headquartered in Bridgewater, New Jersey, is one of the largest and fastest growing generics pharmaceutical manufacturers in the United States. Founded in 2002, Amneal now has more than 4,000 employees in its operations in North America, Asia, Australia and Europe, working together to bring high quality affordable medicines to patients worldwide. Amneal has significantly expanded its portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas. For more information, visit www.amneal.com.
All trademarks listed in this release are property of their respective owners.
View source version on businesswire.com:http://www.businesswire.com/news/home/20161018005667/en/
CONTACT: Amneal Pharmaceuticals LLC
Jim Luce (sales)
Executive Vice President, Sales & Marketing
Apurva Saraf (business development)
Vice President, Global Corporate Development
Cheryl Lechok Communications
Cheryl Lechok (media)
KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY
INDUSTRY KEYWORD: WOMEN PRACTICE MANAGEMENT HEALTH FITNESS & NUTRITION HOSPITALS PHARMACEUTICAL RETAIL OTHER RETAIL FDA CONSUMER MEDICAL SUPPLIES NURSING GENERAL HEALTH
SOURCE: Amneal Pharmaceuticals
Copyright Business Wire 2016.
PUB: 10/18/2016 07:00 AM/DISC: 10/18/2016 07:00 AM